Liezl Gambe

Sigma Healthcare (ASX:SIG) is reportedly mulling a cross-border bid for British health and beauty giant Boots.

Perma-Pipe International Holdings (NASDAQ:PPIH) reported an expansion in top-line revenue for the first quarter of fiscal year 2026, driven by sustained industrial demand across its primary geographic footprints, though near-term factory start-up friction and heightened regulatory compliance outlays compressed bottom-line margins.

TG Therapeutics (NASDAQ:TGTX) reported positive topline results from an early-stage clinical evaluation of a subcutaneous formulation of its flagship therapy, BRIUMVI, in patients with myasthenia gravis, marking a significant milestone in the company’s strategy to expand the drug's utility beyond its approved indication for multiple sclerosis.

SailPoint (NASDAQ:SAIL) reported a 22% increase in first-quarter revenue, driven by robust enterprise adoption of its software-as-a-service identity management platforms amid tightening regulatory mandates for corporate data security.

Designer Brands (NYSE:DBI) reported a slight expansion in its first-quarter top-line revenue, driven by strong growth within its wholesale division that helped offset softening demand across its core brick-and-mortar storefront network.

Novanta (NASDAQ:NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a developer and manufacturer of specialized minimally invasive surgical consumables, for an upfront cash consideration of $1.2 billion.

NIO (NYSE:NIO) confirmed that the U.S. Department of Defense has added the company to its updated list of "Chinese military companies," prompting a swift pushback from the electric vehicle manufacturer as it prepares to contest the designation.

Rumours of a massive Ethereum insider sell-off spread across social media this week after claims emerged that co-founder Vitalik Buterin had sold 110,000 ETH worth approximately $170 million in a matter of hours.

Apple (NASDAQ:AAPL) has launched a new suite of parental safety features explicitly inspired by Australia's world-first social media age ban.

Imugene (ASX:IMU) announced that the US FDA has granted Fast Track Designation to its novel therapy, azer-cel.